Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsASX:TRJ -2.50%32 EV-to-EBIT is 26.00 as of Aug. 10, 2026, which is 46% below its 10-year median of 47.95. GuruFocus rates ASX:TRJ with a GF Score™ of 32/100 and a GF Value™ of A$1.16 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Trajan Group Holdings ranks worse than 67.16% on this metric.
The historical rank and industry rank for Trajan Group Holdings's EV-to-EBIT or its related term are showing as below:
ASX:TRJ'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.66 Med: 47.95 Max: 127.71
Current: 26
During the past 5 years, the highest EV-to-EBIT of Trajan Group Holdings was 127.71. The lowest was -8.66. And the median was 47.95.
ASX:TRJ's EV-to-EBIT is ranked worse than 67.16% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.02
vs ASX:TRJ: 26.00
Trajan Group Holdings (ASX:TRJ) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Trajan Group Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was A$152.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trajan Group Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's EV-to-EBIT falls into.
Trajan Group Holdings's current Enterprise Value is A$75.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Trajan Group Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$2.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trajan Group Holdings (ASX:TRJ) has a EV-to-EBIT of 26.00 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trajan Group Holdings and its competitors. This is 46% below median its historical median of 47.95. According to the industry distribution chart, Trajan Group Holdings ranks #317 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 67.2%.
Is Trajan Group Holdings' EV-to-EBIT too high?
Trajan Group Holdings' current EV-to-EBIT of 26.00 is 46% below median its 10-year median of 47.95. The Medical Devices & Instruments industry median EV-to-EBIT is 19.02. Trajan Group Holdings' value of 26.00 is 36.7% above this industry median. Based on the distribution chart, Trajan Group Holdings ranks #317 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trajan Group Holdings has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #317 out of 472 companies for EV-to-EBIT. This places Trajan Group Holdings in the lower half of its industry. The industry median EV-to-EBIT is 19.02. Trajan Group Holdings' value of 26.00 is 36.7% above this benchmark. While the company's 10-year median is 47.95 vs. the industry median of 19.02, Trajan Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.02, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current EV-to-EBIT of 26.00 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current EV-to-EBIT is 26.00, which is 46% below median its own 10-year median of 47.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (ASX:TRJ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.16, compared to a current price of A$0.20 — trading 83.2% below its estimated fair value. The current EV-to-EBIT is 26.00, which is 46% below median its 10-year median of 47.95 and 36.7% above the Medical Devices & Instruments industry median of 19.02. Trajan Group Holdings' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Trajan Group Holdings (ASX:TRJ), the current EV-to-EBIT is 26.00 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (ASX:TRJ) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of A$0.20 is trading 83.2% below its estimated GF Value™ of A$1.16.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for ASX:TRJ:
EV-to-EBIT: 26.00 (46% below median its 10-year median of 47.95)
GF Value™: A$1.16 vs. price of A$0.20 (83.2% below fair value)
Industry Position: 36.7% above the Medical Devices & Instruments median (#317 of 472)
No single metric tells the full story. See the ASX:TRJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
32GF Score
Get the complete analysis for ASX:TRJ
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRJ has been successfully added to your 
